NEC Corporation (6701.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

20.6x

EV/EBITDA

10.9x

Market Cap

JPY 6.30T

MomentumView details →

1D Return

−0.96%

YTD Return

−9.08%

RSI (14)

53.9

ValuationView details →

P/E (Fwd)

20.6x

EV/EBITDA

10.9x

Market Cap

JPY 6.30T

RSI (14)

53.9

MomentumView details →

1D Return

−0.96%

YTD Return

−9.08%

ProfitabilityView details →

Gross Margin

32.97%

Net Margin

7.54%

EBITDA Margin

14.36%

ROE (TTM)

11.84%

ROA (TTM)

6.05%

Asset Turnover

0.84x

GrowthView details →

Revenue YoY

+4.65%

EPS YoY

−41.43%

FCF YoY

+68.87%

Revenue CAGR 3Y

+2.64%

EPS CAGR 3Y

−21.81%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.14x

Current Ratio

1.57x

Quick Ratio

1.46x

Div Yield

0.68%

Div Rate

JPY 38.00

Div Growth 1Y

−72.86%

Financials snapshotView financials →

Revenue (TTM)

3.58T

Net Income (TTM)

270.23B

Op. CF (TTM)

438.46B

Next earningsNov 3, 2026 →

Latest newsMore news →

NEC unveiled a facial recognition payment service at SoftBank's Takeshiba headquarters employee cafeteria in Tokyo's Minato ward, in collaboration with SB Payment Service and SB C&S.21h ago

Transgene and NEC Corporation announced that TG4050, an individualized neoantigen therapeutic vaccine, achieved 100% three-year disease-free survival in a Phase 1 trial for head and neck cancer, and published results in Nature Communications.2d ago

Similar companies

Fujitsu Limited6702.T Renesas Electronics Corporation6723.T IBIDEN CO.,LTD.4062.T TDK Corporation6762.T FANUC CORPORATION6954.T KYOCERA CORPORATION6971.T Find similar companies →

Latest newsMore news →

NEC unveiled a facial recognition payment service at SoftBank's Takeshiba headquarters employee cafeteria in Tokyo's Minato ward, in collaboration with SB Payment Service and SB C&S.21h ago Transgene and NEC Corporation announced that TG4050, an individualized neoantigen therapeutic vaccine, achieved 100% three-year disease-free survival in a Phase 1 trial for head and neck cancer, and published results in Nature Communications.2d ago